Form D · Other

Orpheus Bioscience, Inc.

Manassas, VA · CIK 0001707212

Offering snapshot reported Jun 25, 2019 · SEC filing

Reported sold
$3.16M
Offering amount: $5M
Investors reported
38
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 11, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 25, 2019Initial$3,157,125No comparison38SEC filing
Jul 6, 2017Amendment$1,255,000$0vs Jun 7, 201720SEC filing
Jun 7, 2017Amendment$1,255,000-$200,000vs May 22, 201720SEC filing
May 22, 2017Initial$1,455,000No comparison20SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$316K (estimated)
Finders' fees
$0
Form D file number
021-342680
In addition to cash compensation, a sales commission in the form of warrants to acquire shares of the Issuer is issued based on a percentage of shares sold.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
David Lanskowsky4221686GP Nurmenkari Inc. · CRD 153480

Source: Form D, filed Jun 25, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
John Abeles Director
Cohava Gelber Director
Guy Yachin Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
9385 Discovery Blvd. #115
Manassas, VA, 20109